Pain management of newly diagnosed sarcoma patients at a single center

Author:

Yang Peiyi1ORCID,Su Yan1ORCID,Zhao Wen1ORCID,Duan Chao1,Li Ying2,Zhou Yuchen1,Wang Li3,Cai Siyu4,Zhou Xuan5,Ni Xin6,Ma Xiaoli1

Affiliation:

1. Medical Oncology Department, Pediatric Oncology Center,Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China

2. Department of Pharmacy, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

3. Nursing Department, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

4. Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

5. Stem cell Transplantation Department, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

6. Pediatric Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China.

Abstract

Background: Systematic pain management of children is insufficient in China, and there is no literature on pain in children with sarcoma. Methods: Clinical data of 188 patients with newly diagnosed sarcoma admitted to the Medical Oncology Department of Beijing Children’s Hospital was collected from October 2018 to December 2020. Children experiencing pain received analgesic treatment and regular assessment. Results: Thirty-seven patients (19.7%) suffered from pain. Six cases (16.2%) had mild pain, 17 (46.0%) moderate, and 14 (37.8%) severe. Daily lives of 31 patients were affected by pain. Twenty-six cases had bone invasion. The analgesic rate was 54.1% before admission and 89.2% after admission. Nine cases were treated with oral morphine regularly, and their pain was relieved before chemotherapy; the dose of morphine was 0.14 ± 0.034 mg/kgQ4H when the target was reached. No serious adverse reactions were observed. The period of morphine application after chemotherapy was 5 to 9 days, and there was no withdrawal reaction. Conclusion: Pain in children with newly diagnosed sarcoma was mainly moderate to severe, and the incidence of pain in sarcoma with bone invasion was higher, with greater intensity. Patients who received standardized pain assessment and regular analgesics reached pain relief quickly, and no serious adverse reactions were observed within the recommended dosage.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference15 articles.

1. Perspectives on cancer pain assessment and management in children.;Duffy;Semin Oncol Nurs,2019

2. Barriers to pediatric pain management: a brief report of results from a multisite study.;Czarnecki;Pain Manag Nurs,2019

3. Shanghai Expert Consensus on Cancer Pain Diagnosis and Treatment (2017 Edition) (癌症疼痛诊疗上海专家共识2017年版).;Hu;China Oncol,2017

4. Beijing Cancer Pain Management Standards (2017 Edition)(北京市癌症疼痛管理规范2017年版).;Chin J Pain Med,2017

5. The psychometric properties of the FLACC scale used to assess procedural pain.;Crellin;J Pain,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3